The effect of Ixeprop in the treatment of ankylosing spondylitis is quite good for most patients, although there are cases where the treatment is not effective. Iceptab is a biologic anti-tumor necrosis factor alpha antagonist that has powerful anti-inflammatory, analgesic and anti-inflammatory effects, and also slows the progression of the disease. The majority of patients respond well to Ixeprop treatment, and its adverse reactions are relatively mild, usually only manifested as local injection site skin redness or swelling or discomfort, usually in about 24 hours can be relieved, but because of the relatively expensive, so patients often can not adhere to the reasonable regular application, so it is best to apply other anti-rheumatic drugs to improve the condition of treatment.